Literature DB >> 22044885

Targeting Eph receptors with peptides and small molecules: progress and challenges.

Roberta Noberini1, Ilaria Lamberto, Elena B Pasquale.   

Abstract

The Eph receptors are a large family of receptor tyrosine kinases. Their kinase activity and downstream signaling ability are stimulated by the binding of cell surface-associated ligands, the ephrins. The ensuing signals are bidirectional because the ephrins can also transduce signals (known as reverse signals) following their interaction with Eph receptors. The ephrin-binding pocket in the extracellular N-terminal domain of the Eph receptors and the ATP-binding pocket in the intracellular kinase domain represent potential binding sites for peptides and small molecules. Indeed, a number of peptides and chemical compounds that target Eph receptors and inhibit ephrin binding or kinase activity have been identified. These molecules show promise as probes to study Eph receptor/ephrin biology, as lead compounds for drug development, and as targeting agents to deliver drugs or imaging agents to tumors. Current challenges are to find (1) small molecules that inhibit Eph receptor-ephrin interactions with high binding affinity and good lead-like properties and (2) selective kinase inhibitors that preferentially target the Eph receptor family or subsets of Eph receptors. Strategies that could also be explored include targeting additional Eph receptor interfaces and the ephrin ligands.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22044885      PMCID: PMC3319464          DOI: 10.1016/j.semcdb.2011.10.023

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  63 in total

1.  EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity.

Authors:  Mitchell Koolpe; Rosemary Burgess; Monique Dail; Elena B Pasquale
Journal:  J Biol Chem       Date:  2005-02-18       Impact factor: 5.157

Review 2.  Targeting protein-protein interactions for cancer therapy.

Authors:  David C Fry; Lyubomir T Vassilev
Journal:  J Mol Med (Berl)       Date:  2005-11-11       Impact factor: 4.599

Review 3.  EphA2 as a target for ovarian cancer therapy.

Authors:  Charles N Landen; Michael S Kinch; Anil K Sood
Journal:  Expert Opin Ther Targets       Date:  2005-12       Impact factor: 6.902

Review 4.  Eph receptor signalling casts a wide net on cell behaviour.

Authors:  Elena B Pasquale
Journal:  Nat Rev Mol Cell Biol       Date:  2005-06       Impact factor: 94.444

5.  An efficient rapid system for profiling the cellular activities of molecular libraries.

Authors:  Jonathan S Melnick; Jeff Janes; Sungjoon Kim; Jim Y Chang; Daniel G Sipes; Drew Gunderson; Laura Jarnes; Jason T Matzen; Michael E Garcia; Tami L Hood; Ronak Beigi; Gang Xia; Richard A Harig; Hayk Asatryan; S Frank Yan; Yingyao Zhou; Xiang-Ju Gu; Alham Saadat; Vicki Zhou; Frederick J King; Christopher M Shaw; Andrew I Su; Robert Downs; Nathanael S Gray; Peter G Schultz; Markus Warmuth; Jeremy S Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

Review 6.  Between a rock and a hard place?

Authors:  Adrian Whitty; Gnanasambandam Kumaravel
Journal:  Nat Chem Biol       Date:  2006-03       Impact factor: 15.040

7.  Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice.

Authors:  Jessica L Dries; Susan D Kent; Jitka A I Virag
Journal:  J Physiol       Date:  2011-01-31       Impact factor: 5.182

8.  An ephrin mimetic peptide that selectively targets the EphA2 receptor.

Authors:  Mitchell Koolpe; Monique Dail; Elena B Pasquale
Journal:  J Biol Chem       Date:  2002-09-25       Impact factor: 5.157

Review 9.  Eph receptor tyrosine kinases in angiogenesis: from development to disease.

Authors:  Dana M Brantley-Sieders; Jin Chen
Journal:  Angiogenesis       Date:  2004       Impact factor: 9.596

10.  Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity.

Authors:  Jill E Chrencik; Alexei Brooun; Michael I Recht; Michelle L Kraus; Mitchell Koolpe; Anand R Kolatkar; Richard H Bruce; Georg Martiny-Baron; Hans Widmer; Elena B Pasquale; Peter Kuhn
Journal:  Structure       Date:  2006-02       Impact factor: 5.006

View more
  42 in total

Review 1.  Eph receptor signaling and ephrins.

Authors:  Erika M Lisabeth; Giulia Falivelli; Elena B Pasquale
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

2.  Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis.

Authors:  Matthew D Dun; Robert J Chalkley; Sam Faulkner; Sheridan Keene; Kelly A Avery-Kiejda; Rodney J Scott; Lasse G Falkenby; Murray J Cairns; Martin R Larsen; Ralph A Bradshaw; Hubert Hondermarck
Journal:  Mol Cell Proteomics       Date:  2015-06-03       Impact factor: 5.911

3.  Discovery of a novel chemotype of tyrosine kinase inhibitors by fragment-based docking and molecular dynamics.

Authors:  Hongtao Zhao; Jing Dong; Karine Lafleur; Cristina Nevado; Amedeo Caflisch
Journal:  ACS Med Chem Lett       Date:  2012-08-23       Impact factor: 4.345

4.  Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer.

Authors:  Katsuaki Ieguchi; Yoshiro Maru
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

5.  JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer.

Authors:  Wenqiang Song; Yufang Ma; Jialiang Wang; Dana Brantley-Sieders; Jin Chen
Journal:  Cancer Res       Date:  2014-03-07       Impact factor: 12.701

6.  EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer.

Authors:  Apurva R Patel; Mahavir Chougule; Mandip Singh
Journal:  Pharm Res       Date:  2014-05-29       Impact factor: 4.200

7.  Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.

Authors:  Srinivas Duggineni; Sayantan Mitra; Roberta Noberini; Xiaofeng Han; Nan Lin; Yan Xu; Wang Tian; Jing An; Elena B Pasquale; Ziwei Huang
Journal:  Biochem Pharmacol       Date:  2012-12-17       Impact factor: 5.858

Review 8.  Eph receptor tyrosine kinases in cancer stem cells.

Authors:  Jin Chen; Wenqiang Song; Katherine Amato
Journal:  Cytokine Growth Factor Rev       Date:  2014-05-17       Impact factor: 7.638

9.  Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.

Authors:  Matteo Incerti; Massimiliano Tognolini; Simonetta Russo; Daniele Pala; Carmine Giorgio; Iftiin Hassan-Mohamed; Roberta Noberini; Elena B Pasquale; Paola Vicini; Silvia Piersanti; Silvia Rivara; Elisabetta Barocelli; Marco Mor; Alessio Lodola
Journal:  J Med Chem       Date:  2013-03-22       Impact factor: 7.446

10.  Targeted delivery of paclitaxel to EphA2-expressing cancer cells.

Authors:  Si Wang; Roberta Noberini; John L Stebbins; Swadesh Das; Ziming Zhang; Bainan Wu; Sayantan Mitra; Sandrine Billet; Ana Fernandez; Neil A Bhowmick; Shinichi Kitada; Elena B Pasquale; Paul B Fisher; Maurizio Pellecchia
Journal:  Clin Cancer Res       Date:  2012-11-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.